Hosted on MSN8d
Nivolumab Added to Chemo Improves Response in ER+, HER2− Breast Cancer
For patients with high-risk, early-stage estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 ...
Targeted Oncology10d
The Targeted Pulse: Sniffing out the Latest From ASCO GI 2025 and Fresh FDA Activity
Aspirin reduced recurrence by 50% in PIK3CA-mutated colorectal cancer, the DCISionRT test earned FDA breakthrough status for predicting radiotherapy benefit in DCIS, and nivolumab plus chemotherapy ...
Targeted Oncology2d
What Community Oncologists Should Watch for at ASCO GU 2025
ASCO Genitourinary Cancers Symposium approaches, several highly anticipated studies are set to shape the future of treatment ...
The American Journal of Managed Care1d
ASCO GU Posters Address Cost-Effectiveness, Implementation Barriers for New mUC Treatments
Health systems are facing hurdles to implementing new and effective metastatic urothelial carcinoma (mUC) therapies into ...
Cancer Therapy Advisor8d
ASCO GI 2025: Practice-Changing Advances in Colorectal Cancer
Three trials presented at ASCO GI 2025 will change practice and improve the treatment of colorectal cancer, according to experts.
Pre-Op Immunotherapy May Help Treat Aggressive Breast Cancers
The immunotherapy used in the trial was nivolumab ( Opdivo ), a drug delivered intravenously that works by disabling a ...
Cure Today8d
Opdivo Plus Chemo May Be Effective and Safe in Older Patients with cHL
Among older adults with classical Hodgkin lymphoma, frontline N-AVD has been found to be highly effective and well-tolerated.
ascopubs.org19d
Focusing on clinical trial ineligibility: Nivolumab plus chemotherapy for patients with advanced gastric cancer.
Q-TWiST analysis of pembrolizumab plus trastuzumab and chemotherapy for patients with metastatic HER2-positive gastric or gastroesophageal junction (G/GEJ) adenocarcinoma in the KEYNOTE-811 trial.